Novo CEO accepts R&D setbacks as CagriSema posts more mixed data and Novo eyes M&A on August 05, 2026 acquisitions blood sugar control bolt-on CagriSema CEO Mike Doustdar Diabetes Mellitus, Non-Insulin-Dependent Eli Lilly Zepbound narrow sales R&D setbacks tirzepatide Wegovy pill Weight Loss ziltivekimab +
Sanofi CFO Defends Hudson's Dupixent Legacy While Acknowledging R&D Setbacks on April 24, 2026 Dosage Forms Dupixent Paul Hudson R&D setbacks sanofi +